05-1154
Anti-JAK1 Antibody, clone 73
clone 73, from mouse
Sign Into View Organizational & Contract Pricing
All Photos(3)
Janus kinase 1, Janus kinase 1 (a protein tyrosine kinase) 1, Tyrosine-protein kinase JAK1
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
73, monoclonal
species reactivity
human, rat, mouse, canine, Xenopus, chicken
technique(s)
immunofluorescence: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG2b
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... JAK1(3716)
General description
JAKs are non-receptor tyrosine kinases which couple to cytokine receptors, and are activated by cytokines. They regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. JAK kinases (JAK1, JAK2, JAK3, Tyk2) have a kinase domain and a second, pseudokinase domain which is not enzymatically active. The principal effectors of JAKs are the STATs (Signal Transducers and Activators of Transcription), which are direct activators of transcription, but JAKs also signal to the Ras-MAP Kinase pathway, and through Tec, to the PI3 Kinase pathway. Immunological stimuli, such as interferons and cytokines, induce recruitment of STAT transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal STAT transcription factors, which subsequently dimerize and translocate to the nucleus where they bind DNA. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor. Among a variety of sites, Tyrosines 1007 and 1008 (Tyr1007/1008) are sites of trans- or autophosphorylation in vivo and in vitro kinase reactions. JAK2 is required for signaling through a different subset of cytokine receptors, while JAK1 is essential for signaling from the IL-2, IL-6 and interferon receptors. JAK3 is required for signaling through cytokine receptors which share a common gamma-chain.
Specificity
Recognizes JAK1 (Janus Kinase 1). The members of the JAK family of cytoplasmic protein tyrosine kinases physically associate with ligand-bound receptors. It is this association that results in tyrosine phosphorylation and activation. JAK1 is approximately 130 kDa and contains a C-terminal tyrosine kinase domain, an adjacent kinase or kinase-related domain, and five other domains that are highly conserved among JAK family members.
Immunogen
Generated from human JAK1, amino acids 551-776.
Application
Anti-JAK1 Antibody, clone 73 detects level of JAK1 & has been published & validated for use in WB, IP & IF.
Immunoprecipitation: A previous lot of this antibody was used in immunoprecipitation under native and denatured conditions.
Immunofluorescence: A previous lot of this antibody was used in IF.
Optimal working dilutions must be determined by end user.
Immunofluorescence: A previous lot of this antibody was used in IF.
Optimal working dilutions must be determined by end user.
Quality
Routinely evaluated by Western Blot on Huvec lysates.
Western Blot Analysis: 1:500 dilution of this lot detected JAK1 on 10 μg of Huvec lysates.
Western Blot Analysis: 1:500 dilution of this lot detected JAK1 on 10 μg of Huvec lysates.
Target description
130 kDa
Linkage
Replaces: MAB3700
Physical form
Format: Purified
Purified mouse monoclonal IgG2b aqueous buffered solution containing 50% glycerol, BSA, and <0.09% sodium azide
Storage and Stability
Stable frozen at -20°C in undiluted aliquots for up to 1 year from date of receipt.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
Analysis Note
Control
Huvec cell lysate, whole Jurkat cell lysate
Huvec cell lysate, whole Jurkat cell lysate
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
TRAF3 enhances type I interferon receptor signaling in T cells by modulating the phosphatase PTPN22.
Science signaling, 15(753), eabn5507-eabn5507 (2022-09-28)
Type I interferons (IFNs) are among the most powerful tools that host cells deploy against intracellular pathogens. Their effectiveness is due both to the rapid, directly antiviral effects of IFN-stimulated gene products and to the effects of type I IFN
Scientific reports, 9(1), 14159-14159 (2019-10-04)
Kinobeads are a set of promiscuous kinase inhibitors immobilized on sepharose beads for the comprehensive enrichment of endogenously expressed protein kinases from cell lines and tissues. These beads enable chemoproteomics profiling of kinase inhibitors of interest in dose-dependent competition studies
Cancer discovery, 8(5), 616-631 (2018-03-03)
Leukemia is caused by the accumulation of multiple genomic lesions in hematopoietic precursor cells. However, how these events cooperate during oncogenic transformation remains poorly understood. We studied the cooperation between activated JAK3/STAT5 signaling and HOXA9 overexpression, two events identified as
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service